Kornimate/medical-research-clean huggingface dataset:
role of imp3 expression in colorectal carcinoma: an immunohistochemical study

Conditions: Colorectal Cancer

Summary: colorectal carcinoma (crc) is the third most common malignancy worldwide. in egypt, the relative frequency of crc is about 9-12% with high male predominance 3:1. the high mortality rates associated with crc is reflective of several factors including: the lack of apparent symptoms in the early stages and the absence of cancer prevention strategies in developing countries. insulin-like growth factor ii m-rna-binding protein 3 (imp3) is a member of the imp family which plays a key role in the transfer and stabilization of mrna, cell growth, and migration during embryogenesis. imp3 has gained considerable interest as a cancer-associated protein. previous studies strongly suggest that imp3 may represent a valuable prognostic marker in human cancer. its overexpression has been reported in a variety of human types of cancer, including lung cancer, colon cancer, pancreatic cancer, gastric cancer, liver cancer, and breast cancer

colorectal carcinoma (crc) is the third most common malignancy worldwide. in egypt, the relative frequency of crc is about 9-12% with high male predominance 3:1. the high mortality rates associated with crc is reflective of several factors including: the lack of apparent symptoms in the early stages and the absence of cancer prevention strategies in developing countries. insulin-like growth factor ii m-rna-binding protein 3 (imp3) is a member of the imp family which plays a key role in the transfer and stabilization of mrna, cell growth, and migration during embryogenesis. to date, there are three known members of imp family proteins: imp1, imp2, and imp3 . imp3 has gained considerable interest as a cancer-associated protein. previous studies strongly suggest that imp3 may represent a valuable prognostic marker in human cancer. its overexpression has been reported in a variety of human types of cancer, including lung cancer, colon cancer, pancreatic cancer, gastric cancer, liver cancer, and breast cancer it has been reported that imp3 expression, determined via immunohistochemistry (ihc), has prognostic significance in crc, recent studies revealed that imp3 expression in tumor cells is a marker of poor prognosis in crc patients and promotes tumor cell proliferation, adhesion, and invasion. despite these observations, the imp3 expression and its clinicopathologic significance in human crc needs further elucidation.

Eligibility criteria:
inclusion criteria: * patients with crc and will be underwent surgery. exclusion criteria: * - patients received pre-operative chemotherapy or radiotherapy. * patients with insufficient clinical data.
phase 1 clinical trial of sodium nitrite for out of hospital cardiac arrest

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: the purpose of this study is to determine the optimal dose of sodium nitrate administered during resuscitation to achieve a plasma level of 10 μm by hospital arrival. pharmacokinetic modeling from human cardiac arrest studies suggest that a single 25 mg iv dose of sodium nitrite will achieve the optimal (based on preclinical studies) neuroprotective plasma levels of 10 μm. in this phase-1 open-label dose finding study in 100 patients, we will determine whether 25 mg iv administered during resuscitation will achieve plasma nitrite levels of at least 10 μm by hospital arrival. dose adjustments, either decreasing or increasing, will be made if necessary permitting us to determine the optimal nitrite dose needed to achieve the 10 μm plasma target. safety data will also be collected


Eligibility criteria:
inclusion criteria: 1. intravenous access/intraosseous access 2. cardiac arrest, either vf or non-vf patients receiving acls by seattle medic one paramedics. 3. age 18 years or older 4. comatose exclusion criteria: 1. traumatic cause of cardiac arrest 2. prisoner, pregnancy, age less than 18 (special population/vulnerable population) 3. known dnar 4. drowning as cause of arrest.
placebo-controlled study evaluating the efficacy and safety of vardenafil in subjects with erectile dysfunction

Conditions: Erectile Dysfunction

Summary: this study tested the hypothesis that vardenafil was both clinically effective and well-tolerated compared to placebo in men diagnosed as being unresponsive to sildenafil.


Eligibility criteria:
inclusion criteria: * men \>/= 18 years of age, with 6 months or longer diagnosis of ed as defined by nih consensus statement, * history of unresponsiveness to sildenafil * stable sexual relationship for \> 6 month exclusion criteria: * primary hypoactive sexual desire * history of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month * nitrate therapy

Keywords: erectile dysfunction vardenafil
effect of continuous glucose monitoring on course of glucose in type 1 diabetes

Conditions: Type 1 Diabetes; Hypoglycemia

Summary: the objective of this cross over study is to access if continuous glucose monitoring (cgms) with a real time feed back and hypoglycemic as well as hyperglycemic glucose alerts vs. only retrospective analysis of glucose values is able to improve course of glucose with special regard to time spent in hypoglycemic glucose ranges in type 1 diabetic patients with impaired hypoglycemia awareness or a history of severe hypoglycemia. the second objective is to access satisfaction with cgms during both conditions

the objective of this cross over study is to access if continuous glucose monitoring (cgms) with a real time feed back and hypoglycemic as well as hyperglycemic glucose alerts vs. only retrospective analysis of glucose values is able to improve course of glucose with special regard to time spent in hypoglycemic glucose ranges. the second objective is to access satisfaction with cgms during both conditions. this study is conducted in an inpatient setting with type 1 diabetic patients. partisans are asked to have twice a continuous glucose measurement with the glucoday system (menarini diagnostics). each measurement period is limited to maximal 48 hours. in one condition the have real time access to current glucose values and alerts are given if glucose is dropping below 70 mg/dl or exceeding 180 mg/dl. during the other condition the participants are blind against their current glucose values and no alerts are given. glucose course is retrospectively analyzed. the order of these two conditions is randomized. expected outcome: the primary outcome variable is the daily time spent in hypoglycemic range in type 1 diabetic patients with and without impaired hypoglycemia awareness or a history of severe hypoglycemia. additionally the patients will also complete questionnaire about satisfaction with cgms, diabetes related distress, treatment satisfaction, depressive and anxiety symptoms which belongs to the secondary variables. inclusion criteria: * type 1 diabetes * age \> 18 years * informed consent exclusion criteria: * diagnosis and/or treatment of a current psychiatric disease * severe late complications

Eligibility criteria:
inclusion criteria: * type 1 diabetes * age \> 18 years * informed consent exclusion criteria: * diagnosis and/or treatment of a current psychiatric disease * severe late complications

Keywords: type 1 diabetes glucose excursion hypoglycemia awareness continuous glucose monitoring
translating the diabetes prevention program (dpp) lifestyle intervention to rural african-american communities (healthy ways)

Conditions: Overweight

Summary: obesity is a significant and growing problem in the us that negatively impacts health and well-being of racial and ethnic minorities, people of low socioeconomic status, and persons living in rural communities and in the south. obesity is a major concern in arkansas, where the obesity rate for adults is higher than the rate for other adults in the nation. however effective weight loss programs are not typically available in these communities. research has shown that the diabetes prevention program (dpp) lifestyle intervention is effective in promoting weight loss in high risk individuals through changes in diet and physical activity that significantly reduce the chances of type 2 diabetes. effective methods are desperately needed to translate the dpp to community settings, where obesity is a compelling public health burden. a major step in translating the dpp is to examine the efficacy of health professionals and community health workers (chws) in delivering the program in real-world settings. this is an important issue from the perspective of how evidence-based weight loss interventions can be provided to underserved, and resource constrained communities that typically may not have access to trained professionals for program delivery. the current project is a 5 year randomized controlled trial that examines dpp delivery and weight outcomes for individuals randomly assigned to either: (1) the dpp intervention delivered by chws or (2) the dpp intervention delivered by health professionals or (3) the self help condition. the study population consists of overweight adults (body mass index (bmi) \> 25) who reside in communities with a high proportion of african americans. primary outcome is change in body weight at 16 months. cost effectiveness and lifestyle behaviors are also evaluated.


Eligibility criteria:
inclusion criteria: 1. non-institutionalized men and women aged 18 and older 2. bmi \[weight (kg)/ height (m2)\] \> 25 3. able to walk for exercise 4. able to provide informed consent 5. willing to accept random assignment exclusion criteria: 1. currently pregnant or nursing, or pregnant within previous 6 months 2. recent heart attack or stroke (in past 6 months) 3. congestive heart failure (nyha class 3-4) 4. history of bariatric surgery or weight loss in excess of 10% in past 6 months 5. current use of weight loss medications 6. another member of household enrolled in study 7. presence of significant impairment that might interfere with participation, such as underlying disease likely to limit lifespan, infectious disease (e.g., hiv, tuberculosis), substantial cognitive impairment, renal dialysis, diagnosis of schizophrenia, psychosis or substance abuse, or other condition that might compromise participation or for which weight loss is not recommended 8. plans to move from the area within the study period
the impact of traction assisted esd on procedural time and outcome

Conditions: Colorectal Polyp

Summary: the aim of this study is to evaluate the role of traction assisted esd in comparison to traditional esd on procedural time and outcome in patients with large, non pedunculated colorectal polyps.

endoscopic polypectomy, has been proven to reduce colorectal cancer incidence and mortality. smaller lesions and pedunculated lesions can be removed by conventional polypectomy, endoscopic mucosa resection (emr). however, large sessile and flat lesions are difficult to remove en bloc with emr, resulting in a high level of tumor recurrence. endoscopic submucosal dissection (esd) was developed during the 1990s in japan to achieve en bloc resection of large neoplasms in the stomach but has in recent years also been extended into management of large (\>2 cm) and technically challenging colorectal polyps. large series on the efficacy of esd in removing benign lesions show high en bloc resection rates resulting in low numbers of recurrences. traction assisted esd was developed in japan to further improve the technique and reduce procedural time, the literature on the efficacy of traction assisted esd is however scarce and limited to japanese studies. the aim in this study is to investigate the impact of this novel technique in comparison to traditional esd on procedural time, en bloc resection rate, r0 resection rate and complication incidence.

Eligibility criteria:
inclusion criteria: * \> 2cm, flat or sessile colorectal polyp exclusion criteria: * recurrencies.

Keywords: esd traction assisted esd polypectomy clip and thread esd
autologous ebv-specific cytotoxic t cells for the treatment of systemic lupus erythematosus (sle)

Conditions: Serologically Active Adult Systemic Lupus Erythematosus

Summary: ebv has been implicated in pathogeny of sle with increase in ebv sero-prevalence, defective control in ebv infection and altered both b and t immune responses to this virus the main objective of this pilot proof-of-concept (poc) study is to evaluate safety and efficacy of autologous ebv specific ctl adoptive transfer in adult patients with serologically active sle

systemic lupus is a disabling disease of the young woman, whose treatment is based on the long-term corticosteroid, anti-malarials and immunosuppressants synthesis. this support is not without potential side effects. ebv is a herpes causes infectious mononucleosis virus, usually encounter in childhood or adolescence, and that our natural immunity cell (cd8 t cells) controls all our lives, not eliminate. increasingly scientific studies show that there are patients with systemic lupus (and multiple sclerosis), a failure of self-control of the ebv virus, by t lymphocytes (cd8). this uncontrolled virus then stimulate the b lymphocytes, which produce antibodies, toxic in lupus. the laboratory isolate t cells specific for ebv (ebv-ctl) of a patient, and stimulate in culture to strengthen them. they can be then re-injected by a single intravenous infusion (autotransfusion), and were used to control the virus in certain diseases where ebv has a demonstrated role post-transplant lymphoproliferative disorder, chronic fatigue syndrome ebv-induced. our therapeutic approach is completely innovative, as based on the principle of cell therapy, thus not using new drugs, and based on the restoration of the patient's immune system, specific ebv.

Eligibility criteria:
inclusion criteria: * 4 systemic lupus criteria of the american college of rheumatology with antinuclear antibodies\> 1:80 * age greater than or equal to 18 years * lupus serologically active without active serious disease (kidney, cns) * anti-native dna ac positive and / or c3 or c4 low * sledai greater than or equal to 2 at baseline * serology hbv, hcv, hiv, htlv-1, syphilis: negative j-30 before sample * hemoglobin \>11g/dl * prednisone dose \<15 mg / day with a stable dose within 30 days previous injection * immunosuppressive treatments which dosage has not been increased for at least 3 months before enrollment * agreement telephone and / or mail for coordinating investigator inclusion * social ensured patient * ebv positive serology exclusion criteria: * evolving severe lupus, requiring high dose corticosteroids and / or immunosuppressive therapy * psychiatric disorders * predicted failure to monitoring compliance with impossibility * infectious episode underway * evolutionary cancer * risk of death within 6 months * consent refusal * pregnancy * nursing women

Keywords: systemic lupus erythematosus autologous anti-ebv ctl adoptive therapy phase 1 -2
risk evaluation and management in heart failure

Conditions: Heart Failure; Risk Factor, Cardiovascular

Summary: this is an prospective study conducted in a chinese heart failure population. the study investigates the effects of cardiovascular disease risk factors such as lifestyle behaviors,biomarkers and intermediate diseases on heart failure prognosis.

heart failure is the main cause of cardiovascular death. the primary goal of this study is to estimate the association of lifestyle behavior (e.g., alcohol, tea and coffee consumption, sedentary behavior, smoking habit, sleep disorder and physical activity), intermediate conditions (e.g., hypertension, diabetes and dyslipidemia), genetic risk factors and circulating biomarkers with heart failure prognosis. another goal is to improve the health status and reduce cardiovascular events and death for heart failure patients via patient education, disease monitoring and medication titration. this study planned to consecutively enroll 1,000 heart failure patients fulfilling the inclusion criteria. each participants will be followed up for at least 5 years. the study endpoints, all-cause mortality and cardiovascular events, will be identified by directly contacting participants during the follow-up surveys, checking pertinent medical records and discharge lists from the hospitals, or checking death certificates from local vital statistics offices. the cox proportional hazard model will be used to estimate the risk factors for health outcomes in heart failure patients.

Eligibility criteria:
inclusion criteria: * aged 18 and above * inpatient with one of the following clinical situations: * congestive heart failure (pulmonary edema,pulmonary congestion or peripheral edema) * cardiogenic shock * insufficient high output cardiac * with impaired cardiac function diagnosed by echocardiography * able to provide informed consent exclusion criteria: * expressed refusal to participate in the baseline investigation or follow-up visits severe co-morbidity associated with a reduction in life expectancy of less than 12 months

Keywords: heart failure risk factor cardiovascular disease lifestyle behavior
pharmacogenetic dosing of warfarin

Conditions: Stroke; Venous Thrombosis; Atrial Fibrillation; Atrial Flutter

Summary: purpose: warfarin is now the most commonly used oral anticoagulant. this drug has inter-individual variability due to the genetic polymorphisms in the warfarin metabolizing enzyme, cyp2c9 and warfarin target, vkorc1. the investigators' team developed a pharmacogenetic dosing algorithm which can predict patients required warfarin dose, thus could prevent warfarin induced warfarin adverse events. methods: the investigators recruited patients with indications for warfarin, the genotypes of vkorc1 and cyp2c9 were determined by the hospitals and verified by national center for genome medicine. the investigators then randomized the patients to one of three arms: 1. warfarin dose predicted by dosing algorithm developed by the international warfarin pharmacogenetic consortium (iwpc), 2. algorithm developed by the taiwan warfarin consortium and 3. standard of care. the investigators aimed to determine whether using genetic dosing algorithm can lead to more stable dose and safer use of the drug.


Eligibility criteria:
inclusion criteria: * patients must give their informed consent and complete the case report form. * patients must be over the age of 20. * patients have clinical indications for warfarin therapy but do not have any prior warfarin treatment. exclusion criteria: * patients who did not complete the informed consent form or the crf * patients who are less than the age of 20. * patients who had prior or is currently on warfarin treatment. * patients who have hemorrhagic tendencies or hemorrhagic diseases defined as copious bleeding caused by viral or bacterial infections; cancer and hepatic dysfunction defined as gop and gpt values three times higher than normal value * patients who has vitamin k deficiency * female patients who is currently pregnant
yulex glove prospective study in spina bifida

Conditions: Spina Bifida; Latex Allergy

Summary: this study is to evaluate the safety of yulex gloves when used by individuals who have documented allergy to natural rubber latex from hevea brasiliensis. yulex is a latex from a different plant (guayule) and in previous studies shows no cross-reactivity to hevea latex and has not been allergenic in workers exposed to yulex. the fda has approved yulex gloves for use in the general population and has recognized and labeled these gloves as hevea latex-free. the labeling still includes a precaution that yulex gloves may pose a risk for development of allergy because yulex does contain a small amount of guayule protein. yulex corporation has proposed doing further studies to demonstrate safety and lack of allergenicity in a population that is prone to latex allergy. in the proposed pilot study, the investigators goal is to complete the protocol on 10 adults with spina bifida who are allergic to natural rubber latex who will wear yulex gloves as part of their regular bladder and bowel care for approximately 30 minutes daily over a 3 month period. the investigators anticipate that the investigators will need to recruit and enroll up to 50 study participants to achieve a final sample of 10 adults with complete study data. individuals with a history of anaphylaxis will be excluded from the study. the study participants will be tested for yulex allergy by glove puncture test as well as serology at the beginning and end of the study. the fda devices group has reviewed the study design and agreed that this is a suitable first pilot study.


Eligibility criteria:
inclusion criteria: * individuals with spina bifida between the ages of 18 and 60 who exhibit positive serology to latex (hevea brasiliensis). exclusion criteria: * possible exclusion criteria include age under 18, does not have spina bifida, or does not exhibit positive serology to latex (hevea brasiliensis).
intrapatient comparison of stn and gpi ttis in pd

Conditions: Parkinson Disease

Summary: the goal of this clinical trial is to evaluate the immediate effects and conduct intrapatient comparisons of individualized 130 hz subthalamic nucleus-transcranial temporal interference stimulation (stn-ttis) and globus pallidus internus-transcranial temporal interference stimulation (gpi-ttis) on motor symptoms in patients with early to mid-stage parkinson's disease (pd) during "on" medication states. the main questions this study aims to answer are: 1. is the therapeutic effect of stn-ttis superior to that of gpi-ttis? 2. what is the degree of improvement in motor symptoms of parkinson's disease patients after receiving stn-ttis or gpi-ttis during the "on" medication phase? researchers will compare the mds-updrs-iii improvement scores of ttis therapy at different targets. participants are required to: 1. visit the clinic twice within two weeks for therapy and testing. 2. record their symptoms and scores.

this clinical trial aims to explore which targets are better for improving pd motor symptoms. patients were randomly assigned to either group a or group b. group a first received stn-ttis therapy, followed by gpi-ttis therapy; group b received the treatments in the reverse order. each session lasted 20 minutes, and patients were in the on-medication state for both treatments. the order of sessions was randomized, with at least 7 days of washout between sessions to avoid carryover effects. mds-updrs-iii evaluations were assessed before and after each treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of primary parkinson's disease (mds); * hoehn \& yahr stage \< 3; * antiparkinsonian drugs must have remained unchanged in the past four weeks, and the dosage must have remained stable throughout the study. exclusion criteria: * presence of neurological disorders that may affect the study (e.g., traumatic brain injury); * history of antipsychotics, antidepressants, or dopamine modulators outside of pd drugs; * metal devices in the head or heart (e.g., deep brain stimulators, pacemakers); * unstable vital signs.

Keywords: subthalamic nucleus globus pallidus internus transcranial temporal interference stimulation